ArticleCell cycle (Georgetown, Tex.)2019

HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.

Jiayao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.